SAGE Stock Latest News

Sage Therapeutics resumed with an Underperform at BofA

PremiumThe Fly

1M ago

SAGE Therapeutics Announces CMO Resignation and Interim Appointment

PremiumCompany Announcements

2M ago

Sage Therapeutics Chief Medical Officer to step down

PremiumThe Fly

2M ago

SAGE Therapeutics: Hold Rating Amid Gradual Growth Prospects and Market Challenges

PremiumRatings

2M ago

PremiumThe FlySage Therapeutics price target established at JPMorgan

2M ago

Company Announcements

SAGE Therapeutics Faces Legal Challenges: Potential Impact on Financial Stability and Growth

2M ago

Ratings

Hold Rating for SAGE Therapeutics: Inventory Challenges and Strategic Prospects

2M ago

SAGE Therapeutics’ Earnings Call: ZURZUVAE’s Success Amid Challenges

PremiumCompany Announcements

2M ago

Sage Therapeutics price target lowered to $12 from $14 at Scotiabank

PremiumThe Fly

2M ago

Sage Therapeutics price target lowered to $7 from $9 at Baird

PremiumThe Fly

2M ago

Cautious Outlook on SAGE Therapeutics Amid Strategic Uncertainty and Pipeline Ambiguities

PremiumRatings

2M ago

PremiumThe FlySage Therapeutics price target lowered to $8 from $9 at Canaccord

2M ago

Ratings

SAGE Therapeutics: Hold Rating Amid Uncertainty and Strategic Exploration

2M ago

Ratings

Hold Rating on SAGE Therapeutics Amid Underwhelming Sales and Strategic Uncertainties

2M ago

Sage Therapeutics price target lowered to $12 from $14 at H.C. Wainwright

PremiumThe Fly

2M ago

Sage Therapeutics Reports Strong 2024 Performance

PremiumCompany Announcements

2M ago

SAGE Therapeutics: Hold Rating Amid Financial Challenges and Uncertain Outlook

PremiumRatings

2M ago

Sage Therapeutics says existing cash to support operations through mid-2027

PremiumThe Fly

2M ago

PremiumThe FlySage Therapeutics reports Q4 EPS , consensus ($1.36)

2M ago

Pre-Earnings

SAGE Earnings Report this Week: Is It a Buy, Ahead of Earnings?

2M ago

The Fly

Sage Therapeutics price target raised to $9 from $6 at Mizuho

3M ago